Register Login

Annexon Inc (ANNX)

(10% Negative) Annexon Inc (ANNX) Announces Delay in milestones Trials for Autoimmune Disease Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 8:51 p.m.

    📋 Annexon Inc (ANNX) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 07:05:13

    Event Type: Clinical Trial Update

    Event Details:

    Annexon Inc (ANNX) Announces Clinical Trial Update Annexon Inc (ANNX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: milestones, benefit
    • Diseases/Conditions: Autoimmune Disease, Guillain-Barré Syndrome (GBS)
    • Clinical Stage: Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Autoimmune Disease
      • Expected in 2026
      • anticipated in 2026
      • expected in second half of 2026

    🔬 Clinical Development Pipeline (Annexon Inc):

    Product Type Development Stage Therapeutic Area Source
    Intravenous immunoglobulin DRUG Phase PHASE1 Guillain-Barré Syndrome ClinicalTrials.gov
    Tanruprubart DRUG Phase PHASE3 Guillain-Barre Syndrome ClinicalTrials.gov
    ANX1502 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Vonaprument DRUG Phase PHASE3 Geographic Atrophy ClinicalTrials.gov
    Sham Administration OTHER Phase PHASE3 Geographic Atrophy ClinicalTrials.gov
    ANX007 BIOLOGICAL Phase PHASE1 Open-angle Glaucoma ClinicalTrials.gov
    Placebos DRUG Phase PHASE1 Safety and Tolerability in Healthy Volunteers ClinicalTrials.gov
    IVIg DRUG Phase PHASE1 Safety and Tolerability in Healthy Volunteers ClinicalTrials.gov
    ANX005 DRUG Phase PHASE1 Safety and Tolerability in Healthy Volunteers ClinicalTrials.gov
    Sham Procedure OTHER Phase PHASE1 Open Angle Glaucoma ClinicalTrials.gov
    5.0mg ANX007 BIOLOGICAL Phase PHASE1 Open Angle Glaucoma ClinicalTrials.gov
    2.5mg ANX007 BIOLOGICAL Phase PHASE1 Open Angle Glaucoma ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Safety and Tolerability in Healthy Volunteers ClinicalTrials.gov
    ANX009 DRUG Phase PHASE1 Safety and Tolerability in Healthy Volunteers ClinicalTrials.gov
    Sham comparator OTHER Phase PHASE2 Geographic Atrophy ClinicalTrials.gov
    ANX105 BIOLOGICAL Phase PHASE1 Healthy ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Annexon Inc
    • Ticker Symbol: ANNX

Search

News categories